• 1
    Lindor KD, Gershwin ME, Poupon R, Kaplan M, Bergasa NV, Heathcote EJ. Primary biliary cirrhosis. HEPATOLOGY 2009; 50: 291308.
  • 2
    Leung PS, Chuang DT, Wynn RM, Cha S, Danner DJ, Ansari A, et al. Autoantibodies to BCOADC-E2 in patients with primary biliary cirrhosis recognize a conformational epitope. HEPATOLOGY 1995; 22: 505513.
  • 3
    Hamlyn AN, Sherlock S. The epidemiology of primary biliary cirrhosis: a survey of mortality in England and Wales. Gut 1974; 15: 473479.
  • 4
    Gross RG, Odin JA. Recent advances in the epidemiology of primary biliary cirrhosis. Clin Liver Dis 2008; 12: 289303.
  • 5
    Metcalf J, James O. The geoepidemiology of primary biliary cirrhosis. Semin Liver Dis 1997; 17: 1322.
  • 6
    Witt-Sullivan H, Heathcote J, Cauch K, Blendis L, Ghent C, Katz A, et al. The demography of primary biliary cirrhosis in Ontario, Canada. HEPATOLOGY 1990; 12: 98105.
  • 7
    Villeneuve JP, Fenyves D, Infante-Rivard C. Descriptive epidemiology of primary biliary cirrhosis in the province of Quebec. Can J Gastroenterol 1991; 5: 174178.
  • 8
    Kim WR, Lindor KD, Locke GR 3rd, Therneau TM, Homburger HA, Batts KP, et al. Epidemiology and natural history of primary biliary cirrhosis in a US community. Gastroenterology 2000; 119: 16311636.
  • 9
    Hurlburt KJ, McMahon BJ, Deubner H, Hsu-Trawinski B, Williams JL, Kowdley KV. Prevalence of autoimmune liver disease in Alaska Natives. Am J Gastroenterol 2002; 97: 24022407.
  • 10
    Steinke D, Weston T, Morris A, MacDonald T, Dillon J. Incidence, prevalence and resource use of primary biliary cirrhosis in Tayside, Scotland [Abstract]. J Hepatol 2001; 34: 532A.
  • 11
    James OF, Bhopal R, Howel D, Gray J, Burt AD, Metcalf JV. Primary biliary cirrhosis once rare, now common in the United Kingdom? HEPATOLOGY 1999; 30: 390394.
  • 12
    Sood S, Gow PJ, Christie JM, Angus PW. Epidemiology of primary biliary cirrhosis in Victoria, Australia: high prevalence in migrant populations. Gastroenterology 2004; 127: 470475.
  • 13
    Iezzoni LI. Coded data from administrative sources. In: Iezzoni LI, ed. Risk adjustment for measuring health care outcomes. 3rd ed. Chicago: Foundation of the American College of Healthcare Executives, 2003.
  • 14
    Myers RP, Quan H, Hubbard JN, Shaheen AA, Kaplan GG. Predicting in-hospital mortality in patients with cirrhosis: results differ across risk adjustment methods. HEPATOLOGY 2009; 49: 568577.
  • 15
    Myers RP, Leung Y, Shaheen AA, Li B. Validation of ICD-9-CM/ICD-10 coding algorithms for the identification of patients with acetaminophen overdose and hepatotoxicity using administrative data. BMC Health Serv Res 2007; 7: 159.
  • 16
    Myers RP, Liu M, Shaheen AA. The burden of hepatitis C virus infection is growing: a Canadian population-based study of hospitalizations from 1994 to 2004. Can J Gastroenterol 2008; 22: 381387.
  • 17
    Myers RP, Papay KD, Shaheen AA, Kaplan GG. Relationship between hospital volume and outcomes of esophageal variceal bleeding in the United States. Clin Gastroenterol Hepatol 2008; 6: 789798.
  • 18
    Myers RP, Shaheen AA, Fong A, Wan A, Swain MG, Hilsden RJ, et al. Validation of coding algorithms for the identification of patients with primary biliary cirrhosis using administrative data. Can J Gastroenterol. In press.
  • 19
    Data Disclosure Handbook. Edmonton, Alberta, Canada: Alberta Health and Wellness, 2003.
  • 20
    Quan H, Cujec B, Jin Y, Johnson D. Acute myocardial infarction in Alberta: temporal changes in outcomes, 1994 to 1999. Can J Cardiol 2004; 20: 213219.
  • 21
    Ludwig J, Dickson ER, McDonald GS. Staging of chronic nonsuppurative destructive cholangitis (syndrome of primary biliary cirrhosis). Virchows Arch A Pathol Anat Histol 1978; 379: 103112.
  • 22
    Theal JJ, Toosi MN, Girlan L, Heslegrave RJ, Huet PM, Burak KW, et al. A randomized, controlled crossover trial of ondansetron in patients with primary biliary cirrhosis and fatigue. HEPATOLOGY 2005; 41: 13051312.
  • 23
    Myers RP, Shaheen AA, Swain MG, Lee SS, Cole S, Coffey-Williamson S, et al. Rituximab for primary biliary cirrhosis (PBC) refractory to ursodeoxycholic acid (UDCA) [Abstract]. HEPATOLOGY 2007; 46: 550A.
  • 24
    Jackson H, Solaymani-Dodaran M, Card TR, Aithal GP, Logan R, West J. Influence of ursodeoxycholic acid on the mortality and malignancy associated with primary biliary cirrhosis: a population-based cohort study. HEPATOLOGY 2007; 46: 11311137.
  • 25
    Calgary Health Region. Quality, Safety, and Health Information. Calgary Health Region Historical Population. Available at: Accessed July 2008.
  • 26
    Statistics Canada. Profile of age and sex, for Canada, provinces, territories, census divisions and census subdivisions, 2001 census. Available at: Accessed March 2006.
  • 27
    Cameron AC, Trivedi PK. Regression Analysis of Count Data. Cambridge, UK: Cambridge University Press, 1998.
  • 28
    Kizilisik TA, Larsen IM, Bain VG, Kneteman NM. Liver transplantation at the University of Alberta Hospitals: a review of the first three years. Transplant Proc 1993; 25: 22032205.
  • 29
    Kaplan EL, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457481.
  • 30
    Ederer F, Axtell LM, Cutler SJ. The relative survival rate: a statistical methodology. Natl Cancer Inst Monogr 1961; 6: 101121.
  • 31
    Statistics Canada. Life tables, Canada, provinces and territories. Available at: Accessed August 2008.
  • 32
    Therneau TM, Grambsch PM. Modeling Survival Data: Extending the Cox Model. New York: Springer-Verlag, 2000.
  • 33
    Lee J, Belanger A, Doucette JT, Stanca C, Friedman S, Bach N. Transplantation trends in primary biliary cirrhosis. Clin Gastroenterol Hepatol 2007; 5: 13131315.
  • 34
    Mendes FD, Kim WR, Pedersen R, Therneau T, Lindor KD. Mortality attributable to cholestatic liver disease in the United States. HEPATOLOGY 2008; 47: 12411247.
  • 35
    Poupon RE, Balkau B, Eschwege E, Poupon R. A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. UDCA-PBC Study Group. N Engl J Med 1991; 324: 15481554.
  • 36
    Lindor KD, Dickson ER, Baldus WP, Jorgensen RA, Ludwig J, Murtaugh PA, et al. Ursodeoxycholic acid in the treatment of primary biliary cirrhosis. Gastroenterology 1994; 106: 12841290.
  • 37
    ter Borg PC, Schalm SW, Hansen BE, van Buuren HR. Prognosis of ursodeoxycholic acid-treated patients with primary biliary cirrhosis. Results of a 10-yr cohort study involving 297 patients. Am J Gastroenterol 2006; 101: 20442050.
  • 38
    Poupon RE, Bonnand AM, Chretien Y, Poupon R. Ten-year survival in ursodeoxycholic acid-treated patients with primary biliary cirrhosis. The UDCA-PBC Study Group. HEPATOLOGY 1999; 29: 16681671.
  • 39
    Pares A, Caballeria L, Rodes J. Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic Acid. Gastroenterology 2006; 130: 715720.
  • 40
    Prince M, Chetwynd A, Newman W, Metcalf JV, James OF. Survival and symptom progression in a geographically based cohort of patients with primary biliary cirrhosis: follow-up for up to 28 years. Gastroenterology 2002; 123: 10441051.
  • 41
    Koulentaki M, Moscandrea J, Dimoulios P, Chatzicostas C, Kouroumalis EA. Survival of anti-mitochondrial antibody-positive and -negative primary biliary cirrhosis patients on ursodeoxycholic acid treatment. Dig Dis Sci 2004; 49: 11901195.
  • 42
    Springer J, Cauch-Dudek K, O'Rourke K, Wanless IR, Heathcote EJ. Asymptomatic primary biliary cirrhosis: a study of its natural history and prognosis. Am J Gastroenterol 1999; 94: 4753.
  • 43
    Corpechot C, Carrat F, Bahr A, Chretien Y, Poupon RE, Poupon R. The effect of ursodeoxycholic acid therapy on the natural course of primary biliary cirrhosis. Gastroenterology 2005; 128: 297303.
  • 44
    Roll J, Boyer JL, Barry D, Klatskin G. The prognostic importance of clinical and histologic features in asymptomatic and symptomatic primary biliary cirrhosis. N Engl J Med 1983; 308: 17.
  • 45
    Gershwin ME, Selmi C, Worman HJ, Gold EB, Watnik M, Utts J, et al. Risk factors and comorbidities in primary biliary cirrhosis: a controlled interview-based study of 1032 patients. HEPATOLOGY 2005; 42: 11941202.
  • 46
    Mason A, Xu L, Neuberger J. Proof of principal studies to assess the role of the human betaretrovirus in patients with primary biliary cirrhosis. Am J Gastroenterol 2004; 99: 24992500.
  • 47
    Ala A, Stanca CM, Bu-Ghanim M, Ahmado I, Branch AD, Schiano TD, et al. Increased prevalence of primary biliary cirrhosis near Superfund toxic waste sites. HEPATOLOGY 2006; 43: 525531.
  • 48
    Mayo MJ. Natural history of primary biliary cirrhosis. Clin Liver Dis 2008; 12: 277288.